PDS Biotechnology (PDSB) stock price is up over 61% this past year. PDS Biotechnology director, president, and CEO, Dr. Frank Bedu, weighs in on the latest trial results that indicated 100% clinical response for treatment of cervical cancer patients with large tumors using a combination of PDS101 with standard-of-care chemoradiotherapy. All patients had a tumor shrinkage of 60% or greater.
22 Jan 2023
Morning Trade Live
14 Nov 2022
Market On Close
23 Jan 2023
Morning Trade Live
07 Nov 2022
The Watch List
09 Dec 2022
The Watch List
21 Nov 2022
Market On Close
14 Dec 2022